
Unither Pharmaceuticals is one of 25 "capacity building" winners to benefit from French government support in the fight against COVID-19

Paris (France), 01 December 2021 - On Monday 22 November, during Emmanuel Macron's official visit to Amiens, the French President announced a major strategic project for Unither Pharmaceuticals. The launch of the "Euroject®" project to fill single-dose ready-to-use vaccines using Blow-Fill-Seal (BFS) technology.

Unither Pharmaceuticals is one of the 25 winners of the "Capacity building" call for expressions of interest (AMI) which is intended to contribute directly to the fight against COVID-19. The injectable vaccines project represents an investment of €68 million, of which €34 million (50%) is financed by the French government. "200 jobs in Amiens by 2024 and 1 billion single-dose vaccines per year. The start of these new production lines in dedicated premises will have a major impact on carrying out our mission: to bring the product available for a vast number of people which improves and simplify patients' lives.", says Eric Goupil, CEO of Unither Pharmaceuticals.

"Euroject® is a major innovation based on BFS technology, consisting of a new type of pre-filled syringe in a single-dose, disposable format that can be produced in very large numbers and at very low production costs (unit cost lower than that of the multi-dose vial presentation).



A world-leading
pharmaceutical **CDMO**

